• Explore /
  • Poster
  • / Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.

Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.

Abstract Poster

Authors

null

Salah-Eddin Al-Batran

Institute of Clinical Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany

Salah-Eddin Al-Batran , Claudia Pauligk , Thorsten Oliver Goetze , Jorge Riera-Knorrenschild , Eray Goekkurt , Stefan Angermeier , Frank Kullmann , Peter C. Thuss-Patience , Nils Homann , Thomas Jens Ettrich , Sabine Junge , Ralf Hofheinz , Sylvie Lorenzen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03647969

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4144)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4144

Abstract #

TPS4144

Poster Bd #

247b

Abstract Disclosures

Similar Posters

First Author: Yelena Yuriy Janjigian

First Author: Lin Shen

First Author: Sylvie Lorenzen

First Author: Lin Shen